Company & Sponsor Intelligence
National Institute on Drug Abuse (NIDA)
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials5
Recruiting0
Completed3
Countries1
Therapeutic footprint
other_psychiatryout_of_scopesubstance_use
Indexed studies
NCT00015080Naltrexone in Treatment of Cocaine Dependence - 5
other_psychiatry · United StatesPHASE2
other_psychiatry · United StatesPHASE2
NCT00247689Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics
substance_use · United StatesTERMINATED
substance_use · United StatesTERMINATED
NCT00124696Cocaethylene as a Treatment for Cocaine Dependence - 1
other_psychiatry · United StatesPHASE1
other_psychiatry · United StatesPHASE1
NCT01844687Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana
out_of_scope · United StatesPHASE2
out_of_scope · United StatesPHASE2
NCT00000340Pemoline in the Treatment of Stimulant Dependence - 5
other_psychiatry · PHASE2
other_psychiatry · PHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →